The official journal of the International Diabetes Federation/Western Pacific Region
Guide for Authors
EDITORS
Editor-in-Chief: Professor Stephen Colagiuri, Sydney, Australia Associate Editors: • Professor
Massimo Massi-Benedetti, Perugia, Italy • Professor John Gerich, Rochester, USA • Professor Russell S. Scott, Christchurch,
New Zealand • Professor Wayne H-H. Sheu, Taichung, Taiwan
Manuscript Submission
Manuscripts should be submitted
online at http://ees.elsevier.com/diab and the instructions on the site should be followed closely. Authors may submit
manuscripts and track their progress to final decision. Reviewers can download manuscripts and submit their reports to the Editors.
The full contact details for the Editorial Office are shown below:
Diabetes Research and Clinical Practice Editorial Office,
Elsevier Ltd., The Boulevard, Langford Lane,
Kidlington, Oxford, OX5 1GB, UK;
Phone: +44 (0) 1865 843753
Fax: +44 (0) 1865 843977
Email: Diab@elsevier.com
Journal Principles
All manuscripts submitted to Diabetes Research and Clinical
Practice should report original research not previously published or being considered for publication elsewhere, make explicit any
conflict of interest, identify sources of funding and generally be of a high ethical standard.
Submission of a manuscript to this
journal gives the publisher the right to publish that paper if it is accepted. Manuscripts may be edited to improve clarity and expression.
Submission of a paper to Diabetes Research and Clinical Practice is understood to imply that it has not previously been published
and that it is not being considered for publication elsewhere.
Authorship
All authors should have made substantial contributions
to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data,
(2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.
Acknowledgements
All contributors who do not meet the criteria for authorship as defined above should be listed in an
acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance,
or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify
the entity that paid for this assistance.
Ethics
Studies involving humans must be performed in accordance with the principles
relating to the Declaration of Helsinki (1964). The manuscript should contain a statement that the work has been approved by the appropriate
ethical committees related to the institution(s) in which it was performed and that subjects gave informed consent to the work. Studies
involving experiments with animals must state that their care was in accordance with institution guidelines. Patients' and volunteers'
names, initials, and hospital numbers should not be used.
Clinical Trials
All randomised controlled trials submitted to Diabetes Research and Clinical Practice whose primary purpose is to affect clinical practice (phase 3 trials) must be registered
in accordance with the principles outlined by the International Committee of Medical Journal Editors (ICMJE; http://www.icmje.org/).
ICJME-approved registries currently include the following: 'ClinicalTrials.gov';www.ISRCTN.org';,'www.actr.org.au';,
'www.umin.ac.jp';, and 'www.trialregister.nl';. Please include the unique trial number and registry name on
manuscript submission.
Conflict of Interest Statement
All authors must disclose any financial and personal relationships
with other people or organisations that could inappropriately influence (bias) their work, all within 3 years of beginning the work submitted.
If there are no conflicts of interest, authors should state that there are none. This statement will be included in the published article.
Article Types
N.B. For reasons of available space, manuscripts that exceed the required word limits (below) will be
declined automatically. All articles other than Editorials and Letters to the Editor are subject to full peer review.
1. Editorials
are either written or commissioned by the Editors and should not exceed 1000 words (not including a maximum of 20 references; one small
figure can be included).
2. Commentaries (1000 words not including a maximum of 20 references and one small figure) offer
a stimulating, journalistic and accessible insight into issues of common interest. They are usually commissioned by the Editors but unsolicited
articles will be considered. Debates comprise two commentaries of opposing or contrasting opinion written by two different groups of
authors. Controversial opinions are welcomed as long as they are set in the context of the generally accepted view.
3. Original
Research Articles should be designated either (a) Basic Research (b) Clinical Research or (c) Epidemiology
and should be a maximum of 5000 words. The word limit includes a maximum of five figures or tables with legends, but does not include
up to 50 references and an abstract of up to 200 words structured according to Aims, Methods, Results, Conclusions and Keywords.
Divide the manuscript into the following sections: Title Page; Structured Abstract; Introduction; Subjects, Materials and Methods; Results;
Discussion; Acknowledgements; References; figures and tables with legends.
4. Brief Reports should not exceed 1000 words,
including a summary of no more than 50 words (but not including up to 20 references) and may be a preliminary report of work completed,
a final report or an observation not requiring a lengthy write-up.
5. Review articles should be a maximum of 5000 words,
including a summary of no more than 100 words (not including up to 75 references) with subheadings in the text to highlight the content
of different sections. Reviews are generally commissioned by the Editors but unsolicited articles will be considered.
6. Letters
to the Editor should be no more than 400 words.
As of 1st July 2007, for reasons of increased manuscript submission rate
and available space, Brief Reports and Letters to the Editor will only be published electronically but will be listed in the print Table
of Contents. These articles can be cited by Digital Object Identifier (DOI) rather than page number.
Manuscript Format
Style. Headlines and subheadlines should be employed liberally in the Methods, Results, and Discussion sections. Use short
paragraphs whenever possible. Clarity of expression, good syntax and the avoidance of jargon is appreciated by the editors and readers.
Abbreviations should be explained in the text.
The Title Page should include authors' names, highest earned degrees, academic
addresses, address for correspondence, and grant support. Authorship should be assumed only by those workers who have contributed materially
to the work and its report. Colleagues who have otherwise assisted or collaborated should be recognized in the Acknowledgment
section, as should sources of funding. The title should be informative and concise. Avoid use of extraneous words such as "study," "investigation," etc. If data from the manuscript have been presented at a meeting, list the full name, date and location of
the meeting and reference any previously published abstracts in the bibliography.
The Abstract, of no more than 200 words,
should be written with particular care since this will be the only part of the article studied by some readers. In the first sentence
state what has been done. Special technical features of the methods should then be noted. The results should be summarized, and the most
important data and supporting statistical correlations should be included. In the final sentence, the authors should emphasize the importance
they attach to their observations. Key Words should be provided in the manuscript; normally 3-5 items should be included.
The Introduction should be brief and set out the purposes for which the study has been performed.
The Materials and Methods
should be sufficiently detailed so that readers and reviewers can understand precisely what has been done without studying the references
directly. The description may be abbreviated when well-accepted techniques are used.
The Results should be presented precisely
and concisely. Keep discussion of their importance to a minimum in this section of the manuscript.
The Discussion should relate
directly to the study being reported with clear conclusions plus a perspective on possible future research. Do not include a general
review of the topic.
References. The author(s) is/are responsible for the accuracy and completeness of the references, which
should be identified in the text by Arabic numerals within square brackets in the order of first citation (i.e. [1,2]) and listed in
numerical order at the end of the text. References must include author(s) last name(s), preceded by initials (listing all authors if
six or fewer, or the first six authors followed by et al. if seven or more), title of article, title of journal abbreviated
according to the Index Medicus, volume (and supplement if appropriate), year of publication in parentheses, and first and last page numbers.
References to books must include author(s) last name(s) preceded by initials, title of chapter, editor(s) last name(s) and initials,
title of book, place of publication, publisher, year of publication, and first and last page numbers. 'Articles in press' can be included
in the reference list but submitted work under consideration at a publisher must be cited in the main text as 'Author X, unpublished
data'. Draft analyses can be referred to in the main text as 'Author X, personal communication'.
Journal Reference Example
1. A. Ramachandran, C. Snehalatha, V. Vijay et al. Derivation and validation of diabetes risk score for urban Asian Indians. Diab. Res.
Clin. Prac. 70 (2005) 63-70.
Book Reference Example
1. P. Drury, W. Gatling, Diabetes: Your Questions Answered, Churchill
Livingstone, Edinburgh, 2005.
Figures must be suitable for high-quality reproduction. Lettering should be complete, of professional
quality, and of a size appropriate to that of the illustration or drawing, with the necessary reduction in size taken into account. If,
together with your accepted article, you submit usable colour figures, Elsevier will ensure that these figures appear free-of-charge
in colour in the electronic version of your accepted article, regardless of whether or not these illustrations are reproduced in colour
in the printed version. Colour illustrations can only be included in print if the additional cost of reproduction is contributed by the
author: you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please go to http://ees.elsevier.com/diab
and click on the Artwork Guidelines.
Supplementary files offer the author additional possibilities to publish supporting applications,
movies, animation sequences, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be
published online alongside the electronic version of your article in Elsevier web products, including ScienceDirect: http://www.sciencedirect.com.
In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of our recommended file
formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption
for each file.
Tables should be numbered consecutively with Arabic numerals, and contain only horizontal lines. Provide a
short descriptive heading and explanation above each table with footnotes underneath.
The Language of the journal is English.
Upon request, Elsevier will direct authors to an agent who can check and improve the English of their paper (before submission). Please
contact authorsupport@elsevier.com for further information.
Publisher Services
Proofs will be sent
to the authors for careful checking. Changes or additions to the edited manuscript cannot be allowed at this stage. Corrected
proofs should be returned to the publisher within stated deadlines.
Elsevier will do everything possible to get your article corrected
and published as quickly and accurately as possible. Therefore, it is important to ensure that all of your corrections are sent back
to us in one communication. Subsequent corrections will not be possible, so please ensure your first sending is complete.
Fast-track
Publication. The journal aims for prompt publication of all accepted papers. Submissions containing new and particularly important
data may be fast-tracked for peer review and publication; this is a limited facility and is strictly at the discretion of Editors.
Page Charges will not be made.
Offprints/Reprints. The corresponding author, at no cost, will be provided with a PDF
file of the article. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover
image and a disclaimer outlining the terms and conditions of use. Paper offprints can be ordered by the authors. An order form with prices
will be sent to the corresponding author.
Special Subject Repositories
Certain repositories such as PubMed Central ('PMC')
are authorized under special arrangement with Elsevier to process and post certain articles. The following agreements have been established
for authors whose articles have been accepted for publication in an Elsevier journal and whose underlying research is supported by one
of the following funding bodies: • National Institutes of Health: Elsevier will send a version of the author's accepted
manuscript that includes author revisions following peer-review for public access posting 12 months after final publication. Because
the NIH 'Public Access' policy is voluntary, authors may elect not to deposit such articles in PMC. If you wish to 'opt out' and not
deposit to PMC, you may indicate this by sending an e-mail to NIHauthorrequest@elsevier.com. More information regarding
the agreement between Elsevier and the National Institutes of Health can be found at http://www.elsevier.com/wps/find/authorshome.authors/nihauthorrequest • The Wellcome Trust: Elsevier will send to PMC the version of the author's manuscript that reflects all author-agreed
changes including those made post peer review, for public access posting immediately after final publication. Authors are required to
initially subsidize their manuscript with fees reimbursed by the Wellcome Trust. Wellcome Trust authors, whose manuscripts are subsidized,
will have the corresponding articles made free to non-subscribers on ScienceDirect www.sciencedirect.com and Elsevier's
electronic publishing platforms. More information regarding the agreement between Elsevier and The Wellcome Trust can be found at http://www.elsevier.com/wps/find/authorshome.authors/wellcometrustauthors
